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Essentials
• Phosphoinositide 3-kinase and MAPK pathways crosstalk via PDK1.
• PDK1 is required for adenosine diphosphate-induced platelet activation and thromboxane generation.
• PDK1 regulates RAF proto-oncogene Ser/Thr kinase (Raf1) activation in the MAPK pathway.
• Genetic ablation of PDK1 protects against plateletdependent thrombosis in vivo.
Summary. Background: Platelets are dynamic effector cells with functions that span hemostatic, thrombotic and inflammatory continua. Phosphoinositide-dependent protein kinase 1 (PDK1) regulates protease-activated receptor 4-induced platelet activation and thrombus formation through glycogen synthase kinase3b. However, whether PDK1 also signals through the ADP receptor and its functional importance in vivo remain unknown. Objective: To establish the mechanism of PDK1 in ADP-induced platelet activation and thrombosis. Methods: We assessed the role of PDK1 on 2MeSADP-induced platelet activation by measuring aggregation, thromboxane generation and phosphorylation events in the presence of BX-795, which inhibits PDK1, or by using platelet-specific PDK1 knockout mice and performing western blot analysis. PDK1 function in thrombus formation was assessed with an in vivo pulmonary embolism model. Results: PDK1 inhibition with BX-795 reduced 2-methylthio-ADP (2MeSADP)-induced aggregation of human and murine platelets by abolishing thromboxane generation. Similar results were observed in pdk1 À/À mice. PDK1 was also necessary for the phosphorylation of mitogen-activated protein kinase kinase 1/2 (MEK1/2), extracellular signalregulated kinase 1/2, and cytosolic phospholipase A2, indicating that PDK1 regulates an upstream kinase in the mitogen-activated protein kinase (MAPK) pathway. We next determined that this upstream kinase is Raf-1, a serine/threonine kinase that is necessary for the phosphorylation of MEK1/2, as pharmacological inhibition and genetic ablation of PDK1 were sufficient to prevent Raf1 phosphorylation. Furthermore, in vivo inhibition or genetic ablation of PDK1 protected mice from collagen/
Introduction
Platelets are involved in many processes, ranging from fighting microbial infections and triggering inflammation to promoting tumor angiogenesis and metastasis [1] [2] [3] [4] [5] [6] [7] [8] [9] . Nevertheless, one of the primary physiological functions of platelets is maintaining homeostasis of the circulatory system by forming hemostatic thrombi that prevent blood loss and maintain vascular integrity [10] [11] [12] [13] . When there is vascular damage, exposure of the extracellular matrix results in the recruitment and activation of platelets, thereby leading to aggregation and the formation of a fibrin-rich hemostatic plug at the injured site. Platelet activation is associated with platelet shape change, secretion of granule contents (ADP and serotonin), and activation of the fibrinogen receptor, resulting in platelet aggregation [14] [15] [16] [17] . Activated platelets also generate the important lipid mediator thromboxane A 2 (TxA 2 ), which serves to recruit other platelets to the site of injury and reinforces the platelet plug [16, [18] [19] [20] . Thromboxane generation induced by 2-methylthio-ADP (2MeSADP) is coordinated by P2Y purinoceptor 1 (P2Y 1 ), P2Y purinoceptor 12 (P2Y 12 ), and integrin a IIb b 3 . Inhibition of either extracellular signal-regulated kinase 1/2 (ERK1/2) or protein tyrosine kinase 2 (Pyk2) activation results in abolished thromboxane generation in ADP-stimulated platelets. 2MeSADP-induced ERK1/2 phosphorylation occurs independently of outside-in signaling via mitogen-activated protein kinase kinase 1/2 (MEK1/2), Src family kinases (SFKs), and phosphoinositide 3-kinase (PI3K). Thromboxane is generated from its precursor arachidonic acid through cyclooxygenase pathways, which act as a positive feedback mediator to amplify the initial platelet functional responses and reinforce the stability of the hemostatic plug. Previous studies have shown that ADPinduced thromboxane generation depends on both insideout and outside-in pathways [16, 21] . In particular, ERK1/ 2 activation during inside-out signaling through P2Y receptors plays a critical role in TxA 2 generation, as ERK1/2 is important for cytosolic phospholipase A2 (cPLA2) phosphorylation and activation [22] [23] [24] . Inhibition of PI3Kb abolishes ERK1/2 activation when platelets are stimulated with ADP [24] . However, the mechanism through which the PI3K pathway regulates the phosphorylation and activation of ERK1/2 has not been identified.
Phosphoinositide-dependent protein kinase 1 (PDK1), a member of the protein A, G and C (AGC) family of proteins, is a Ser/Thr protein kinase that phosphorylates and activates other protein kinases from the AGC family, all of which mediate cellular responses [25] [26] [27] . Chen et al. demonstrated that aggregation of PDK1-deficient platelets was reduced in response to thrombin and U46619 [28] . For thrombin signaling, this involved a IIb b 3 -mediated outside-in signaling. They further showed that activation of PDK1 with thrombin inhibits glycogen synthase kinase 3b (GSK3b) (a major substrate of PDK1), thereby enhancing thrombin-induced platelet functional responses and thrombus formation. In other studies, Dangelmaier et al. demonstrated that inhibition of PDK1 by BX-795, a well-characterized and specific inhibitor of PDK1, impaired platelet aggregation and protein kinase B (Akt) Thr308 phosphorylation [29] .
However, thrombin and ADP activate via distinct signaling pathways. These published data suggested to us an unknown component to the PDK1-ADP-thromboxane signaling pathway, and prompted us to investigate the thromboxane-related mechanisms whereby PDK1 regulates ADP-induced platelet activation and thrombosis. The mechanism by which PDK1 controls ADP-induced platelet activation has not been examined, and its role in thromboxane B 2 (TxB 2 ) generation is not known. It is important fo fill these knowledge gaps, especially as PDK1 has recently gained attention as a potential drug target for thrombosis and cancer [30] [31] [32] [33] [34] [35] [36] [37] [38] , and a deeper understanding of the mechanism by which PDK1 acts may shed light on clinical outcomes when PDK1 inhibitors are being used.
In the present study, we demonstrate that PDK1, which is activated downstream of the PI3K pathway, plays a crucial role in 2MeSADP-induced platelet aggregation and thromboxane generation by regulating the mitogenactivated protein kinase (MAPK) pathway. We show that pharmacological blockade or genetic deletion of PDK1 in platelets abolishes 2MeSADP-induced thromboxane generation and the activation of critical MAPK pathway proteins (e.g. Raf1, MEK1/2, and ERK1/2). Moreover, inhibition or deletion of PDK1 reduces death from pulmonary embolism in vivo. Therefore, we conclude that crosstalk between the MAPK and PI3K pathways via PDK1 is crucial for 2MeSADP-induced platelet activation, thromboxane generation, and thrombosis.
Materials and methods
Reagents 2MeSADP (Cat. no. 1624) was from Tocris (Minneapolis, MN, USA). Epinephrine, SB-216763 and apyrase (type VII) were from Sigma (St Louis, MO, USA). BX-795 was from Selleckchem (Houston, TX, USA). MSC 2032964A and Whatman protein nitrocellulose transfer membrane were from Fisher Scientific (Pittsburg, PA, USA). LI-COR Odyssey blocking buffer was from LI-COR Biosciences (Lincoln, NE, USA). Phospho-Raf1 (Ser338), phospho-MEK1/2 (Ser217/221), phospho-Erk1/2 (Thr202/Tyr204), phospho-cPLA (Ser505), phospho-PDK1 and phosphoGSK3b antibodies were from Cell Signaling Technology (Beverly, MA, USA). Phospho-myelin basic protein (MBP), total MEK1/2 and b-actin antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). from the institutional review board for these studies. Informed consent was provided prior to blood donation.
Murine platelet isolation
Washed murine platelets were prepared as previously described [39] . Platelet counts were determined with a Hemavet 950FS blood cell counter (Drew Scientific, Dallas, TX, USA). The platelet count was adjusted to 2 9 10 8 cells mL À1 for all of the studies.
Aggregation
Aggregation was measured with a lumi-aggregometer (Chrono-Log, Havertown, PA, USA) at 37°C under stirring. Washed platelets (0.5 mL) were stimulated with different agonists, and the change in light transmission was measured. In selected experiments, platelets were preincubated with different inhibitors before agonist stimulation.
Western blotting
Protein samples for platelets treated with or without the inhibitors, followed by stimulation with 2MeSADP, were prepared, and western blotting was performed to analyze phosphorylation events, as previously described [40] .
Measurement of TxA 2 generation
Washed platelets were prepared at a concentration of 2 9 10 8 platelets mL
À1
. Stimulations were performed for 3.5 min, and the reaction was stopped by snap freezing. Levels of TxB 2 were determined in duplicate with a Correlate-EIA TxB 2 enzyme immunoassay kit (Assay Designs, Ann Arbor, MI, USA), according to the manufacturer's instructions.
MEK1/2 kinase assay
Washed human platelets (1 9 10 9 cells mL
À1
) were stimulated with 2MeSADP in the presence and absence of BX-795. The reaction was stopped by the addition of an equal volume of cold 2x NP40 lysis buffer (2x Lysis Buffer: 50 mM HEPES, pH 7.4, 100 mM NaCl, 2 mM EGTA, and 2% NP40, plus Halt protease and phosphatase inhibitors), and the samples were rocked at 4°C for 30 min. Samples were centrifuged at 12 000 9 g at 4°C for 10 min. Supernatants were transferred to clean tubes, and 5 lg of anti-MEK1/2 was added. Samples were rocked for 1 h at 4°C, 50 lL of washed TRUBLOT anti-mouse IgG IP beads (Rockland, Limerick, PA, USA) was, added and rocking was performed for an additional 1 h at 4°C. Beads were washed three times with 1X lysis buffer and once with kinase buffer (50 mM MOPS [pH 7.4], 5 mM MgCl 2 , 5 mM MnCl 2 , and 1 mM dithiothreitol). The kinase reaction was started by adding kinase buffer (50 lL) containing 10 lL (20 lg) of MAPK substrate cocktail, 10 lL of kinase buffer solution, and 10 lL of Mg 2+ -ATP, and was incubated for 20-30 min in a 30°C shaking incubator. Reactions were terminated by the addition of 20 mM EDTA. Beads were pelleted by centrifugation, 1500 g for 5 min and 30 lL of supernatant was mixed with 10 lL of 4X sample buffer for measurement of MBP phosphorylation. All samples were boiled for 10 min. The samples were subjected to 12% SDS-PAGE. The non-radioactive MEK1/2 activation assay kit (EMD Millipore, Burlington, MA, USA) was used for this experiment.
Pulmonary embolism model
Thromboembolism experiments were performed as described previously, with anesthetized pdk1 fl/f and pdk1 Sigma-Aldrich) in 100 lL of phosphate-buffered saline was administered through retro-orbital injection or via the vena cava, respectively. Time of cessation of respiration (time to the onset of respiratory arrest that lasted for at least 2-3 min) was recorded. Two minutes after the onset of respiratory arrest, but while the heart was still beating, 0.5 mL of Evans blue solution (1% in saline; Sigma-Aldrich) was injected into the heart.
Statistics
Each experiment was repeated at least three times. Results are expressed as mean AE standard error of the mean with number of observations. Data were analyzed with PRISM. Significant differences were determined with Student's t-test. Differences were considered to be significant at a two-tailed P-value of < 0.05.
Results
PDK1, but not GSK3b, inhibition regulates 2MeSADP-induced platelet aggregation and thromboxane generation in human and mouse platelets
Previous studies with a PDK1 inhibitor and knockout murine platelets have shown that PDK1 plays an important role in platelet activation and thrombus formation [28, 29] . However, the mechanism through which PDK1 regulates 2MeSADP-induced platelet activation has not been elucidated. The functional role of PDK1 in human and murine platelets stimulated with 2MeSADP was investigated by pretreating platelets with BX-795, a selective PDK1 inhibitor. Pretreatment of human and murine platelets with BX-795 abolished secondary aggregation induced by 2MeSADP (Fig. 1A) , with an effect size similar to that seen with platelets treated with aspirin or indomethacin. These results indicate that PDK1 regulates thromboxane generation. Prior work has indicated that PDK1 regulates thrombin-induced platelet activation through the enzyme GSK3b [28] . Thus, we evaluated whether inhibition of GSK3b with SB-216763 (a GSK3b-specific inhibitor) rescues the defect of 2MeSADP-induced platelet aggregation that we observed in BX-795-treated platelets. However, as shown in Fig. 1B , the inhibition of 2MeSADP-induced platelet aggregation was not rescued by GSK3b inhibition in either human or murine platelets. Previous studies have shown that thromboxane plays a key role in secondary aggregation when platelets are stimulated with 2MeSADP [16] . Therefore, we evaluated the effect of PDK1 inhibition on thromboxane generation when platelets were stimulated with 2MeSADP in the presence or absence of BX-795, SB-216763, or both. Figure 1C shows that the PDK1 inhibitor BX-795 almost completely abolished 2MeSADP-induced thromboxane generation, whereas the GSK3b inhibitor did not rescue the thromboxane generation. These data indicate that PDK1 is essential, and GSK3b is dispensable, for 2MeSADP-induced platelet secondary aggregation and thromboxane generation.
PDK1 regulates the MAPK pathway in platelets stimulated with 2MeSADP
In platelets, the MAPK pathway is known to play an important role in thromboxane generation [22] . Nevertheless, crosstalk between the PI3K and MAPK pathways has never been studied in platelets. As ERK1/2 regulates thromboxane generation by phosphorylating cPLA2 [16] , we first evaluated the effect of PDK1 inhibition on ERK1/2 and cPLA2 phosphorylation. We measured Akt (Thr308) phosphorylation in platelets treated with BX-795 as a positive control. As shown in Fig. 2A , phosphorylation of ERK1/2 and cPLA2 was abolished in the presence of BX-795, which suggests that PDK1 regulates thromboxane generation by inhibiting the MAPK pathway.
PDK1 regulates MEK1/2 phosphorylation by controlling Raf1 activation
MEK1/2 is a master kinase that is known to activate ERK1/2 in many cells, including platelets [22, 23] . Saori et al. have shown that inhibition of PDK1 activity by gene silencing or single-nucleotide polymorphism mutation suppresses MEK1/2 activation in cell lines [42] [43] [44] . However, the effect of PDK1 on MEK1/2 activity has not been studied in platelets. To evaluate the effect of PDK1 on MEK1/2 activation, we treated platelets with BX-795 and studied its effect on MEK1/2 Ser221 phosphorylation. As shown in Fig. 2A , 2MeSADP-induced MEK1/2 phosphorylation in platelets was abolished in the presence of BX-795. We also evaluated the kinase activity of MEK1/2 from platelets pretreated with BX-795 that were stimulated with 2MeSADP by using an in vitro kinase assay. MEK1/ 2 that was immunoprecipitated from BX-795-treated and 2MeSADP-activated platelets did not phosphorylate the known and canonical MEK1/2 substrate MBP in vitro, as shown in Fig. 2B . These results further demonstrate that PDK1 plays a crucial role in MEK1/2 activation, and establish that PDK1 plays an important role in thromboxane generation when platelets are stimulated with 2MeSADP. These results also establishe that the PI3K-PDK1 pathway has an important role in 2MeSADP-induced platelet activation and thromboxane generation.
We further studied the mechanism through which MEK1/2 activation is regulated by studying Raf1, a proto-oncogene serine threonine kinase. Studies in other cells have shown that Raf1 regulates MEK1/2 activation [45] , so we studied the effect of PDK1 inhibition on Raf1 by measuring phosphorylation at Ser338, which is known to be important for its activity [46] . As shown in Fig. 2C , inhibition of PDK1 abolished Raf1 phosphorylation and activity. These results further demonstrate that PDK1 plays a crucial role in activation of the Raf1-MEK1/2-ERK1/2 pathway, and establish that the PI3K-PDK1 pathway regulates 2MeSADP-induced platelet activation and thromboxane generation.
Addition of arachidonic acid restored the aggregation defect in BX-795-treated platelets Activation of cPLA2 upon platelet stimulation releases arachidonic acid from phospholipids in the membrane. This arachidonic acid then produces TxA 2 , which is required for ADP-induced platelet aggregation. As we found that PDK1 regulates thromboxane generation via cPLA2 phosphorylation and activation (Figs 12and), we hypothesized that addition of arachidonic acid to BX-795-treated platelets would rescue aggregation defects. We stimulated platelets with 2MeSADP and with or without arachidonic acid in the presence of BX-795. As shown in Fig. 2D , stimulation of platelets with both 2MeSADP and arachidonic acid (purple) fully restored normal platelet aggregation. These results indicate that PDK1 regulates thromboxane generation, thereby controlling platelet aggregation. Recent studies have shown that ASK1 plays an important role in regulating the activation of p38 and thromboxane generation when platelets are stimulated with thrombin, convulxin, or collagen [47] . However, the role of ASK1 in 2MeSADP-induced thromboxane generation has not been 
evaluated. As PDK1 and ASK1 regulate signaling by direct interaction and phosphorylation [48] , we evaluated the role of ASK1 by using MSC 2032964A, an ASK1-specific inhibitor. Platelet aggregation, thromboxane generation and cPLA2 phosphorylation were not abolished when platelets were stimulated with 2MeSADP in the presence of MSC 2032964A (Fig. 3A,B) . Consistent with a previous ASK1 knockout study [47] , ERK1/2 phosphorylation was not inhibited upon treatment with an ASK1 inhibitor, but ERK1/2 phosphorylation was inhibited when platelets were treated with BX-795 or both BX-795 and MSC 2032964A (Fig. 3C,D) . Using SB-203580, a p38-MAPK inhibitor, we found that both p38-MAPK and ERK1/2 are required for activation of cPLA2 when platelets are stimulated with 2MeSADP (Fig. 4A) . Inhibiting ASK1 decreased p38-MAPK kinase activation at lower, but not higher, doses of 2MeSADP (Fig. 4B) , suggesting that, at higher agonist concentrations, p38-MAPK is regulated by a kinase other than ASK1. These results indicate that PDK1, but not ASK1, predominantly regulates 2MeSADP-induced platelet aggregation and thromboxane generation.
Genetic ablation of PDK1 decreases 2MeSADP-induced aggregation, thromboxane generation and thrombus formation in vivo
We evaluated the role of PDK1 in 2MeSADP-induced platelet activation by using platelet-specific PDK1-deficient mice (pdk1 À/À ), and comparing the results with those of studies using the PDK1 pharmacological inhibitor. Consistent with our inhibitor studies (Fig. 1) , PDK1-deficient platelets stimulated with 2MeSADP showed significantly decreased aggregation and a complete absence of thromboxane generation (Fig. 5A,B) . Furthermore, Raf1, MEK1/2, ERK1/2, Akt (Thr308) and cPLA2 phosphorylation were also abolished in PDK1-deficient murine platelets stimulated with 2MeSADP (Fig. 5C ). These results support our pharmacological studies demonstrating that PDK1 controls 2MeSADP-induced platelet aggregation by regulating thromboxane generation.
Finally, we evaluated the effect of PDK1 on thrombosis in vivo. We treated mice with BX-795 in vivo for 5 days, which was necessary to fully inhibit PDK1 activity, on the basis of initial experiments (Fig. 6A,B ) and similar studies [49] . Inhibition of PDK1 with BX-795 significantly improved survival after ADP/epinephrineinduced thromboembolism (Fig. 6C) . We confirmed this in a second thrombosis model, in which inhibition of PDK1 with BX-795 significantly improved survival after collagen/epinephrine-induced pulmonary thromboembolism, as platelet aggregation induced by low doses of collagen depends on thromboxane (Fig. 6D) . Consistent with studies in which PDK1 has been pharmacologically inhibited, the genetic ablation of PDK1 also significantly reduces mortality from pulmonary thromboembolism (Fig. 6E) . Thus, the genetic ablation or pharmacological inhibition of PDK1 reduces platelet-dependent thrombosis mortality in vivo.
Discussion
PDK1 is a Ser/Thr protein kinase that can phosphorylate and activate other protein kinases from the AGC family. PDK1 plays important roles in mediating cellular responses such as cell growth, apoptosis, and angiogenesis [50] [51] [52] [53] [54] [55] . Dysregulated activation of PI3K-PDK1-Akt is common in cancer, and different inhibitors are being developed to block the downstream effectors of this pathway [38, 50, [56] [57] [58] . In our prior studies, we extensively characterized the PDK1 inhibitor BX-795, including its effects on aggregation at different doses and to various agonists such as collagen and AYPGKF [29] . ATP secretion was similarly reduced.
PDK1 also mediates thrombin-mediated and collagenmediated platelet aggregation, ATP secretion, and thromboxane generation [28, 29, 59 ]. However, the mechanism whereby PDK1 mediates ADP-induced platelet activation has never been elucidated. In our study, we used both pharmacological and genetic approaches to identify the mechanism through which PDK1 regulates ADP-induced platelet activation. The results from our study show a Fig. 2 . Phosphoinositide-dependent protein kinase 1 (PDK1) regulates the mitogen-activated protein kinase signaling pathway through phosphorylation of Raf1. (A) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 lM) for 5 min, and this was followed by stimulation with 2-methylthio-ADP (2MeSADP) (50 nM) under stirring for 5 min. Western blots were then probed for phosphorylated Akt (Thr308), Akt (Ser473), glycogen synthase kinase 3b (GSK3b) (Ser9), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (Ser217/221), extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204), and cytosolic phospholipase A2 (cPLA2) (Ser505). The western blots shown are representative of three independent experiments. (B) Washed human platelets were pretreated with BX-795 (1 lM) for 5 min, and this was followed by stimulation with 2MeSADP (50 nM) under stirring for 5 min. Platelets were then lysed in NP40 lysis buffer and immunoprecipitated for MEK1/2. A MEK1/2 kinase activity assay was performed on the platelet lysates to measure phosphorylation of the MEK1/2 substrate myelin basic protein (MBP). The western blot shown is representative of three experiments. (C) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 lM) for 5 min, and this was followed by stimulation with 2MeSADP (50 nM) under stirring for 5 min. Western blots were then probed for phospho-Raf1 (Ser338) and total b-actin. The western blot shown is representative of three independent experiments. (D) Washed human platelets were pretreated with dimethylsulfoxide (DMSO) (vehicle control) or BX-795 (1 lM, 37°C, 5 min), and this was followed by stimulation with 2MeSADP (50 nM) (black and blue), arachidonic acid (10 lM) (red) or both (purple) under stirring. Platelet aggregation was measured by aggregometry. Tracings are representative of three or more independent experiments. novel crosstalk between the PI3K and MAPK pathways that regulates ADP-triggered platelet activation and thromboxane generation via PDK1. PDK1 has two well-studied downstream effectors: Akt and GSK3b. In resting platelets, activated GSK3b binds to its substrate to inhibit platelet activation. However, when platelets are stimulated, PDK1 is activated, and subsequent phosphorylation of GSK3b at Ser9 inhibits its activity. Recent studies by Chen et al. showed that PDK1 inhibition blocks thrombin-induced platelet aggregation and that this defect can be rescued by treating cells with the GSK3b inhibitor SB-216763 [28] . In contrast, whereas our studies also showed that PDK1 inhibition blocks ADP-induced platelet aggregation, SB-216763 did not rescue the aggregation defect when platelets were stimulated with 2MeSADP (Fig. 1B) . These results demonstrate that PDK1 regulates ADP-induced platelet activation through a novel GSK3b-independent mechanism. Studies by Dangelmaier et al. have shown that treatment of platelets with BX-795, a PDK1-specific inhibitor, affected 2MeSADP-induced platelet activation and thromboxane generation [29] . Our study shows that treatment of platelets with BX-795 inhibits 2MeSADP-mediated secondary platelet aggregation similarly to treatment of platelets with aspirin or indomethacin (Fig. 1A) . It is known that 2MeSADP-mediated secondary platelet aggregation is thromboxane-dependent. Therefore, we evaluated the novel mechanism through which PDK1 regulates 2MeSADP-induced platelet thromboxane generation. Our results ( Figs 1C and 4) show that pharmacological inhibition or genetic deletion of PDK1 abolishes thromboxane generation.
Thromboxane generation induced by 2MeSADP is coordinated by P2Y 1 , P2Y 12 , and a IIb b 3 [16] . Studies by Kim et al. and others have also shown that inhibition of either ERK1/2 or Pyk2 activation results in abolition of thromboxane generation in ADP-stimulated platelets [21, 60, 61] . Previous studies have shown that 2MeSADP-induced ERK1/2 phosphorylation occurs independently of outside-in signaling, and that, rather, MEK1/2, SFK and PI3K proteins regulate ERK1/2 activation [21, 24, 60] . Inhibition of MEK1/2 and PI3K with pharmacological inhibitors prevents 2MeSADP-mediated secondary platelet aggregation by abolishing thromboxane generation, similarly to PDK1 inhibition [24] . Taken together, the analyses of these signaling pathways indicate that PDK1 activation downstream of the PI3K pathway regulates the MAPK pathway (Fig. 3C,D) and 2MeSADP-induced thromboxane generation and thrombosis. Previous studies in transfected cell lines have shown that PDK1 is critical for MEK1/2 activation [43] . However, the functional importance of crosstalk between the PI3K pathway and the MAPK pathway has never been studied in platelets until now. Garcia et al. showed that intracellular calcium released downstream of P2Y 1 , and PI3K activation downstream of P2Y 12 , play a crucial role in the activation of ERK2 when cells are stimulated with 2MeSADP [16] . Nevertheless, the mechanism through which the PI3K pathway regulates ERK1/2 activation and thromboxane generation has not been studied. In our study, we found that inhibition or deletion of PDK1 (a Ser/Thr protein kinase activated downstream of the PI3K pathway) resulted in abolition of ERK2 and cPLA2 phosphorylation ( Fig. 2A) . These results suggest that PDK1 regulates the MAPK pathway and also thromboxane generation. Our study also evaluated the effect of PDK1 on MEK1/2 kinase activity, as it is an important upstream kinase for ERK1/2 activation, by using a MEK1/2 kinase assay. As Time shown in Fig. 2B , MEK1/2 activity is abolished in BX-795-treated platelets stimulated with 2MeSADP. These results provide further evidence that the PI3K and MAPK pathways are linked by PDK1. In other cells, Raf1 is an important protein kinase that is crucial for phosphorylation of MEK1/2 [62] . Raf1 is expressed in platelets, and upon stimulation its activity is regulated by intracellular calcium and protein kinase C (PKC) upon stimulation [63, 64] . Interestingly, studies in 2MeSADP-stimulated platelets have shown that inhibition of PKC does not inhibit ERK1/2 phosphorylation and thromboxane generation [65] . These data suggest that Raf1 is regulated by a new Ser/Thr protein kinase other than PKC located downstream of ADP receptors. We evaluated the effect of PDK1 and/or PKC inhibition on Raf1 phosphorylation in platelets stimulated with 2MeSADP. Our results show that Raf1 phosphorylation is abolished in platelets in which PDK1, but not PKC, is inhibited (Fig. 2C) .
Naik et al. demonstrated that ASK1 regulates thromboxane generation and thrombosis when platelets are stimulated with thrombin, collagen or convulxin by abolishing p38-MAPK and cPLA2 phosphorylation [47] . However, the effect of ASK1 deletion on 2MeSADP-induced thromboxane generation has not been studied. In other cells, PDK1 and ASK1 has been shown to directly interact and phosphorylate each other, and act as negative regulators of their respective kinases [48] . We evaluated the effect of PDK1 and ASK1 inhibition on 2MeSADP-induced platelet aggregation, thromboxane generation, and cPLA2 phosphorylation. Figure 3A ,B shows that inhibition of ASK1 (MSC 2032964A) did not abolish 2MeSADP-induced secondary aggregation, thromboxane generation, or cPLA2 phosphorylation, but that these are abolished when platelets are treated with BX-795. We used ERK1/2 phosphorylation as a negative control to determine the specificity of the inhibitor (data not shown), as this protein has been shown to be regulated by ASK1 [47] . We also evaluated the role of p38-MAPK in 2MeSADP-induced platelet activation, and especially cPLA2 activation. Our data (Fig. 4) indicate that both p38-MAPK and ERK1/2 are required for ADP-induced activation of cPLA2. At higher concentrations of 2MeSADP (50 nM), ASK1 inhibition did not fully abolish p38-MAPK activation (Fig. 4B) , suggesting that, under these conditions, ASK1-independent pathways may regulate p38-MAPK activation.
Pharmacological inhibitors, particularly at higher concentrations, may have off-target effects. Akt and GSK3b regulate platelet functions and are downstream effectors of PDK1. Thus, we employed specific inhibitors for Akt and GSK3b, and evaluated their effects on the MAPK pathway. As shown in Fig. 3C,D , Akt or GSK3b inhibitors have no effect on activation of the MAPK pathway. However, when platelets were treated with the PDK1 inhibitor BX-795, in combination with Akt or GSK3b inhibitors, phosphorylation of Raf1-MEK1/2-ERK1/2 was abolished. These results show that PDK1, but not Akt or GSK3b, regulates MAPK pathway activation. We further confirmed the role of PDK1 in the MAPK pathway by using platelet-specific PDK1 knockout mice. Our results in Fig. 5 show that PDK1 deletion has critical effects on MAPK pathway activation, similarly to what we found with BX-795. These results from our study show not only the specificity of the PDK1 inhibitor, but also the role of this important Ser/Thr kinase protein in MAPK pathway activation and platelet activation with ADP. Moreover, our findings demonstrate that this pathway is conserved between humans and mice.
M€ unzer et al. and others have shown that inhibition of PDK1 protects mice from stroke and thrombosis [59] . This study also demonstrates that collagen-mediated adhesion and aggregation is affected by PDK1 inhibition. As thromboxane plays a crucial role in platelet activation when platelets are stimulated with low doses of collagen [66, 67] , we evaluated the effect of PDK1 inhibition on collagen-induced and epinephrine-induced pulmonary embolism in mice treated with BX-795 or PDK1 knockout mice. Our results, obtained with several different models, show that PDK1 inhibition or platelet-specific genetic deletion of PDK1 is protective against thrombosis (Fig. 6) . The coupling of pharmacological inhibitor studies with in vivo models in which PDK1 has been genetically ablated is a strength of our studies. Moreover, we used a specific and well-studied inhibitor of PDK1, i.e. BX-795, at concentrations that minimize off-target effects (Fig. 6A,B) . Nevertheless, BX-795 may affect other cells and tissues, and this point should be considered in future studies investigating BX-795 or similar inhibitors targeting PDK1.
In conclusion, PDK1 regulates 2MeSADP-induced platelet activation and thromboxane generation via the MAPK pathway (Fig. 7) . PDK1, but not PKC, phosphorylates and activates Raf1 in the MAPK pathway when platelets are stimulated with 2MeSADP. Furthermore, PDK1 inhibition protects mice from collagen/epinephrine-induced pulmonary embolism. Our study provides clear evidence for novel crosstalk between the PI3K and MAPK pathways, regulating platelet function via PDK1. 
